- RecruitingPHASE2, PHASE3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
This study compares two drug combinations for advanced uveal melanoma. It looks at RP2 with nivolumab versus nivolumab with ipilimumab, for patients who haven't had these immune-boosting treatments before, to see which works better and is safer.
For: Metastatic Uveal MelanomaUnited States · Australia · United Kingdom - Active not recruitingPHASE1
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
This study is testing a new treatment called RP2, alone and with nivolumab, for adults with advanced cancers. It aims to find the safest dose and see how well it works. RP2 is a modified virus designed to fight cancer.
For: CancerSpain · United Kingdom - AuthorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
For: metastatic uveal melanomaGermany · Italy · France